News | August 26, 2025
Giant antibody in humans acts like a brace against bacterial toxins
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
ICMR will continue to track trends in HMPV circulation throughout the year
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
